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A series of pharmaceutically active compounds including
diclofenac, gemfibrozil, ibuprofen, naproxen, 2-propylpen-
tanoic acid, 4-biphenylacetic acid and tolfenamic acid can be
reversibly intercalated into a layered double hydroxide,
initial studies suggest that these materials may have
application as the basis of a novel tuneable drug delivery
system.
In order for drug therapy to be most effective the desired
pharmacological response must be obtained at the target without
harmful interactions at other sites.1 This requires the correct
amount of drug to be absorbed into the body and transported to
the target with control of the drug rate input in order to produce
the correct dosage. Ideally the delivery of the drug to other
tissues should be minimised or prevented, however this is rarely
achieved owing to the complex nature of these processes.2
Modern controlled release systems are usually polymer based
with mechanisms of release regulated by diffusion, bioerosion,
degradation and swelling or the production of osmotic pressure.
Exposing the polymer–drug mixture to the gastrointestinal fluid
results in the diffusion of the drug from the tablet or capsule and
the polymers are excreted. Certain polymer–drug complexes
undergo bio-erosion or degradation when they pass through the
gastrointestinal tract. Swelling or the generation of osmotic
pressure occurs with other polymer–drug formulations upon
contact with gastrointestinal fluid resulting in the release or
expulsion of the drug.3
Controlled release systems have many advantages but also
have disadvantages. The main advantage is the decreased
fluctuation in drug concentration resulting in reduced toxicity.
In addition, the reduction in the number of doses may lead to
lower patient care time and also to the use of a smaller amount
of drug. However, disadvantages include the increased amount
of time required to achieve therapeutic blood concentrations,
dose dumping and usually an increase in the cost.3 Not all drugs
are suitable for controlled release systems—those not suitable
are drugs with very short or very long half lives, poor absorption
through the gastrointestinal tract and low solubility.4 Controlled
release systems are most useful for drugs that are taken on an
extended basis such as drugs used to treat cardiovascular
disorders and arthritis. Layered double hydroxides (LDHs)
represented by the general formula [MII(12 x)MIIIx(OH)2]-
[An2x/n]·zH2O or [MIMIII2(OH)6][An21/n]·zH2O, where MI, MII
and MIII are mono-, di- and tri-valent metal cations, re-
spectively, are now well established as excellent anion-
exchange materials and their extensive intercalation chemistry
has widespread applications in areas such as heterogeneous
catalysis,5,6 optical materials,7,8 biomimetic catalysis,9,10 sepa-
ration science11,12 and as DNA reservoirs.13,14
Here we report the reversible intercalation of a number of
active cardiovascular and anti-inflammatory agents into a
layered double hydroxide and the results of an initial study into
the use of these drug–inorganic hybrid materials as a novel
tuneable drug delivery system.
As a number of well known cardiovascular, anti-inflamma-
tory and analgesic agents are either carboxylic acids or
carboxylic derivatives we were interested in investigating
whether these compounds could be ion-exchange intercalated in
a layered double hydroxide. [LiAl2(OH)6]Cl·H2O reacts with 2
equivalents of either the sodium salts of diclofenac, gemfibrozil,
ibuprofen, naproxen, 2-propylpentanoic acid, 4-biphenylacetic
acid or tolfenamic acid (Table 1) in H2O at 60 °C for 1–2 h to
give a LDH–drug intercalation compound. The solid products
are isolated by filtration and then washed with an excess of
deionised water and then acetone. In each case full anion
exchange of the interlayer Cl2 anions and intercalation of these
pharmaceutically active compounds has taken place. In each
case the products are first stage intercalation compounds and
they have all been fully characterised using X-ray powder
diffraction (XRD), elemental microanalysis, IR spectroscopy
and thermogravimetric analysis. The observed interlayer spac-
ings for the drug–LDH intercalates are shown in Table 1, the
values are consistent with the formation of bilayer arrangement
for all the drug molecules with the positively charged
[LiAl2(OH)6]+ layers of the host lattice. In all cases the
intercalated anions can be quantitatively recovered from the
host lattice by treatment of the intercalates with either an
aqueous solution of M2CO3 (M = Na or Li) or addition of dilute
HCl. In the case of treatment with an alkali metal carbonate, the
alkali metal salt of the organic guest ions goes into solution and
† Electronic supplementary information (ESI) available: Fig. S1: X-ray
diffraction patterns of (a) [LiAl2(OH)6]Cl·H2O and (b) LDH/Ibuprofen
intercalate. See http://www.rsc.org/suppdata/cc/b1/b106465g/ 
Fig. 1 Release profiles for (a) diclofenac at pH 4 and pH 7 and (b)
gemfibrozil at pH 4 and pH 7.
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the solid phase is quantitatively converted to [LiAl2(OH)6]-
(CO3)0.5·H2O as indicated by the XRD data which shows a
series of 00l reflections corresponding to an interlayer spacing
of 7.51 Å. Addition of dilute aqueous HCl solution to the LDH–
drug complex results in dissolution of the inorganic host and
precipitation of the neutral form of the guest acid.
Given that these ions could be recovered intact from the LDH
host we were interested to see if this could form the basis of a
drug reservoir and controlled release system. Therefore, we
performed a series of experiments in order to quantitatively
monitor the kinetics of release of the guest ions under conditions
which would resemble physiological conditions. Deintercala-
tion of the drugs from the LDH was performed by the addition
of the drug–LDH complex to 250 ml of phosphate buffer
solution at 37 °C of pH 7 or pH 4. A mass of 0.025 g of the
LDH–drug complex was used for 4-biphenylacetic acid,
diclofenac and tolfenamic acid and a larger amount of 0.1 g for
naproxen and gemfibrozil. Aliquots were removed from the
reaction mixture at regular intervals and solution UV–Vis
absorption spectroscopy was used to quantify the concentration
of the de-intercalated ions in the aqueous phase. Fig. 1 shows
release profile plots for the deintercalation of diclofenac and of
gemfibrozil on addition of phosphate buffer at pH 4 and pH 7.
At pH 4 the measured release of diclofenac and gemfibrozil is
very fast with almost full deintercalation observed in less than
10 min. Surprisingly, the release curve for gemfibrozil at pH 7
is almost identical to the profile recorded at pH 4. At pH 7 the
release of diclofenac is much slower and only after 28 min is
90% of the drug released into solution. Table 2 is a summary of
the release profiles for all the different guest ions that we have
intercalated in [LiAl2(OH)6]Cl·H2O.
In summary, the results show that the intercalation of
pharmaceutically active compounds that form stable anions is a
feasible approach for the storage then subsequent controlled
release of bioactive agents. We anticipate that there will be
tremendous scope for fine tuning the intercalation and de-
intercalation kinetics in these materials by employing different
LDHs with differing charge densities and basicities.
Notes and references
1 C. R. Gardner, Biomaterials, 1985, 6, 153.
2 L. F. Prescott, Novel Drug Delivery, 1989, 1.
3 V. V. Ranade, J. Clin. Pharm., 1991, 31, 2.
4 J. E. Shaw, Annu. Rep. Med. Chem., 1980, 15, 302.
5 V. R. L. Constantino and T. J. Pinnavaia, Catal. Lett., 1994, 23, 361.
6 A. Corma, V. Fornes, F. Rey, A. Cervilla, E. Llopis and A. Ribera, J.
Catal., 1995, 152, 237.
7 M. Ogawa and K. Kuroda, Chem. Rev., 1995, 95, 399.
8 H. Tagaya, S. Sato, T. Kuwahara, J. Kadokawa, K. Masa and K. Chiba,
J. Mater. Chem., 1994, 4, 1907.
9 B. Sels, D. De Vos, M. Buntinx, F. Pierard, A. Kirsch-De Mesmaeker
and P. Jacobs, Nature, 1999, 400, 855.
10 L. Ukrainczyk, M. Chibwe, T. J. Pinnavaia and S. A. Boyd, Environ.
Sci. Technol., 1995, 29, 439.
11 A. M. Fogg, V. M. Green, H. G. Harvey and D. O’Hare, Adv. Mater.,
1999, 11, 1466.
12 A. M. Fogg, J. S. Dunn, S. G. Shyu, D. R. Cary and D. OAHare, Chem.
Mater., 1998, 10, 351.
13 J. H. Choy, S. Y. Kwak, Y. J. Jeong and J. S. Park, Angew. Chem., Int.
Ed., 2000, 39, 4042.
14 J. H. Choy, J. S. Park, S. Y. Kwak, Y. J. Jeong and Y. S. Han, Mol. Cryst.
Liq. Cryst. Sci. Technol., Sect. A, 2000, 341, 425.
Table 1 Summary of the guest molecule used and the analytical and structural data of the LDH–drug intercalation compounds
Guest Molecular structure of guesta
Interlayer
spacing/Åb Elemental analysis: found (calc.)c
4-Biphenylacetic acid
(C14H12O2)
20.4 C, 30.77 (30.77); H, 5.16 (5.20); x = 0.58, y = 2
Diclofenac
(C14H10Cl2NaNO2)
22.3 C, 30.91 (30.92); H, 4.12 (3.91); N, 2.60 (2.58); x = 0.72, y = 1
Gemfibrozil (C15H22O3) 23.2 C, 35.35 (35.36); H, 6.56 (6.65); x = 0.69, y = 1
Ibuprofen (C13H18O2) 22.7 C, 31.92 (31.98); H, 6.15 (5.99); x = 0.75, y = 3
Naproxen (C14H14O3) 21.5 C, 27.91 (28.08); H, 4.98 (4.99); x = 0.48, y = 1
2-Propylpentanoic acid
(C8H16O2)
18.7 C, 14.78 (14.82); H, 5.77 (6.04); x = 0.35, y = 1
Tolfenamic acid
(C14H12ClNO2)
21.9 C, 23.24 (23.18); H, 5.25 (5.29); N, 1.90 (1.93); x = 0.46, y = 3
a Neutral guest molecules were converted to the sodium salt prior to intercalation. b Based on hexagonal cell: a = b = 90, g = 120°, a = b = 5.1 Å and
c = 2 3 d(002) c Based on the general formula LixAl2(OH)6[drug]x ·yH2O
Table 2 Release profile data
Release times/mina
pH 4 pH 7
Guest molecules t50b t90b t50b t90b
Diclofenac (lmax = 279 nm) 1 4 1 28
Naproxen (lmax = 317, 330 nm) 1 9 1 17
Gemfibrozil (lmax = 275 nm) 1 5 1 5
Tolfenamic acid (lmax = 290 nm) 1 21 1 23
4-Biphenylacetic acid (lmax = 290
nm) 1 2 1 35
a Release (%) = (It/Imax) 3 100, at lmax. b t50 and t90 are the times for 50
and 90% release, respectively.
Chem. Commun., 2001, 2342–2343 2343
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